When California voters approved spending state money for human embryonic stem (ES) cell research last November, other states began to formulate their own funding plans. However, court battles in California and political machinations elsewhere have slowed efforts by the states to circumvent federal restrictions on such research.
Since 2001, the use of U.S. federal dollars for research on human ES cells has been restricted. Scientists can only use about two dozen human ES cell lines for research funded with federal dollars, which has hampered progress. Work prohibited by the federal policy can continue with private funds, but researchers with private support have had to keep these projects separate from any work bankrolled by federal dollars.
To address the shortfall in federal cash for human ES cell research, a number of U.S. states are looking at ways to raise funds to support such studies, and California is leading the way. Last November, 59% of California voters approved Proposition 71 to create the California Institute for Regenerative Medicine (CIRM). This institute aims to provide $3 billion in stateissued bonds over 10 years for human ES cell research. The strategy is that investors would purchase the bonds, providing money for the research, and in return would receive interest payments on their investment. But a series of lawsuits have stalled the issuing of bonds and the dispersal of funds. One lawsuit argues that the Independent Citizens Oversight Committee-which presides over CIRM-is not under state control, and thus cannot handle state-issued bonds. Another lawsuit contends that committee members may have a conflict of interest because they work for California universities or companies that could reap the benefits of the funding initiative. Although the lawsuits address procedural issues, they are backed by the California Family Bioethics Council and the Life Legal Defense Foundation, groups opposed on ethical grounds to ES cell research. CIRM overcame one hurdle last month when a California judge ruled against a request to nullify parts of Proposition 71, saying that the plaintiffs in the lawsuits had not yet demonstrated that the institute violates California's state constitution. However, the judge did not dismiss the case, which will go to trial in February. The case could remain hung up in courts well into next year, which leaves the funding of CIRM in doubt.
These setbacks "haven't taken momentum out of the interest in stem cell research," says David Peckman, associate director of the Institute for Stem Cell Biology and Medicine at University of California, Los Angeles. "It's of some concern, but it's a political issue that will be resolved," he says. Daniel Perry, president of the Coalition for the Advancement of Medical Research in Washington D.C., agrees: "It's a delay but it will not be fatal." In the meantime, CIRM has subsisted on emergency funding, including a $3 million loan from the state, and a $5 million donation from the foundation of inventor Ray Dolby, which will keep the institute staffed and running through Spring 2006. In a tentative step forward, the CIRM awarded its first set of grants in September this year, allocating $12.5 million for training graduate students, postdoctoral fellows, and clinical researchers at 16 institutions in California. No one knows when the institutions will receive the money, but CIRM says that it will provide funding through so-called bond anticipation notes, a stopgap financing measure that circumvents the need to issue state bonds.
The promise of a windfall for stem cell research funding has attracted some researchers to California. For instance, Stefan Heller, who studies stem cells of the inner ear, left a faculty position at Harvard and moved to Stanford this fall. Proposition 71 helped to entice him. "It played a role for sure," he says. Heller has been surprised by how few of his scientific colleagues have seriously considered moving to California, a fact that he attributes to a lack of interest in leaving communities where researchers have established personal roots. Still, the potential for state research money "was certainly not a decisive issue for me," says Heller. Just as important were opportunities for collaboration at Stanford; teaming up with other researchers was possible at Harvard, he says, but it was difficult with labs spread throughout Boston. "Stanford offers everything in one place," he says. And despite federal restrictions on funding for human ES cell research, Heller points out that researchers can find alternative sources of funding for solid research projects.
A stimulating research environment prompted another stem cell researcher to move in the opposite direction and leave California. Meri Firpo, now at the University of Minnesota, left her previous post as a research professor at the University of California, San Francisco, in April. "I did not contemplate staying" because of the initiative, she says. "I chose based on the research environment I was moving into." She points out that the availability of experts on pancreatic islet transplantation at the University of Minnesota should facilitate moving her research on developing stem cell-based therapies for
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With stringent U.S. federal restrictions on funding for human embryonic stem cell research still in place, states grapple with the issue of whether to fund such research themselves.
diabetes into clinical studies. "Funding is an important aspect but it's really only one point," she says. And in retrospect, "if I had chosen to stay in California, that would have been a mistake" because of the delay in dispersing research money by CIRM.
Other Jersey. The research committee of the state commission is currently reviewing applications for $5 million dollars in state research funding, says Beck, the committee's chair. "We want to be the first state to put money out on the street," he says. Acting Governor of New Jersey Richard Codey also announced plans this year to devote $150 million in state funds to provide a building for the institute. (Jon Corzine was elected governor by New Jersey voters in November; Codey did not run.) In addition, Codey introduced a bill into the New Jersey legislature this year to authorize $230 million in state-issued bonds to fund stem cell research, including work on human ES cells. Wrangling over this and a similar but competing bill prevented passage in time to put a bond measure before New Jersey voters this November. Research advocates aim to have a measure on the ballot next fall. To avoid any concerns about conflicts of interest, the research commission is aiming to keep grant review committees as independent as possible, he says. And "we're aiming to keep a low profile" to avoid the intense media exposure surrounding Proposition 71, says Beck.
The state of Connecticut is also moving into the stem cell research arena. In January 2005, Governor Jody Rell advocated spending $20 million of the state's budget surplus to fund human stem cell research. And in July, lawmakers approved legislation allowing all forms of stem cell research in the state, and appropriated $10 million over 10 years to support the work. The law forbids reproductive cloning but allows therapeutic cloning. Blood stem cell expert Diane Krause of Yale University in New Haven is optimistic the move will attract stem cell researchers to Connecticut. Yale University recently attempted to woo two stem cell researchers, who instead took positions in California, Krause says. Losing top people "is certainly one of our concerns."
In other states, research advocates have met fierce opposition to state-supported stem cell research. The Missouri legislature has considered several bills that would outlaw therapeutic cloning. "That persistent attempt has created an uncertainty that has interrupted expansion of the Stowers Institute," says William Neaves, director of the Kansas City, Missouri, nonprofit research organization, "and have stymied attempts to recruit promising young scientists." To counter the push to ban therapeutic cloning in Missouri, a coalition of advocates launched a campaign in October to put a constitutional amendment on next November's ballot; approval by voters would permit therapeutic cloning and prevent any bans on using this approach. The initiative won't provide any research dollars, says Neaves. "No one expects the state taxpayers to provide funding," but he says that the amendment would help to ensure that Missouri is "a very cordial environment for biomedical research."
Other states have also launched stem cell efforts. In Illinois, Governor Rod R. Blagojevich issued an executive order in July this year that allocated $10 million for stem cell research and the creation of the Illinois Regenerative Medicine Institute. Blagojevich even sent letters to Missouri stem cell researchers in August inviting them to relocate to Illinois. In October, Governor Robert Ehrlich, Jr., of Maryland promised that his agenda for next year would include a stem cell program, after conservative state legislators killed a $25 million bill for stem State funds for stem cell research will likely come in a trickle rather than a flood, but some experts say that private money is sufficient to move the field forward regardless of what happens with state and federal funding. "We do of course hope that the NIH will eventually be able to support all kinds of stem cell research," says Neaves. "But the federal ban has not really affected us. We have sufficient internal funding to enable our scientists to undertake any research they wish." Other institu- Regardless of what transpires in individual states, a change in direction at the federal level is vital for the field, say many researchers. "I do not feel that this is or should be a state issue," said Harvard Stem Cell Institute codirector Douglas Melton in an email. Embryonic stem cell research should be part of a progressive national health care policy, and segregating research efforts doesn't encourage cooperation, he added. The federal restrictions force scientists to pursue research avenues solely to conform to politics, says Peter Mombaerts of the Rockefeller University in New York City, who studies methods for generating stem cell lines through therapeutic cloning in mice. For instance, in October of this year, two teams reported methods for generating human ES cell lines without harming a viable human embryo. "If there were not these restrictions, I would not do this research," says Harvard University stem cell scientist Rudolf Jaenisch, who led one of the groups. As state officials move to resolve problems over funding for human ES cell research, scientists keep their sights on the ultimate goal: a better understanding of stem cell biology and the possibility of therapeutic applications of stem cell research.
